Cellectar Biosciences, Inc.

NASDAQ: CLRB · Healthcare · Biotechnology

PublicHQ Florham Park, NJ · MorrisCIK 0001279704Reports USD

#1 of 1,418 Healthcare companies by revenue

EA Score

——

FH 27DQ —GM —SS 52

v0.1 · 35/100 weight · pillars only

↑ listing tenure, balance-sheet leverage · ↓ Piotroski F, return on equity

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$21.8M

Employees

as of 2026-08-22

Market cap

$20.7M

as of 2026-08-22

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Net income-$21.8M-$21.8M2025

Operating income-$23.0M-$23.0M2025

Total assets$15.0M$15.0M2025

Liabilities$5.1M$5.1M2025

Equity$8.5M$8.5M2025

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

What is Cellectar Biosciences, Inc.’s financial profile?

Cellectar Biosciences, Inc. earned -$21.8M in FY2025 net income.

Peers · Healthcare

NurExone Biologic Inc.——Quantum BioPharma Ltd.——Werewolf Therapeutics, Inc.——ProMIS Neurosciences, Inc.——ImpediMed Limited——Optimi Health Corp.——

Neighbors

Morris →

Zoetis Inc.$9.5B82B+Solstice Advanced Materials Inc.$3.9B54D PBF Energy Inc.$29.3B63C Wyndham Hotels & Resorts, Inc.$1.4B67B Avis Budget Group, Inc.$11.7B59C Lincoln Educational Services Corporation$518.2M72B

Key facts

CEOJames V. Caruso

SectorHealthcare

IndustryBiotechnology

HeadquartersFlorham Park, NJ

ExchangeNASDAQ: CLRB

Employees11

IPO date2005-11-10

Latest filings

10-Q2026-08-13 8-K2026-08-13 8-K2026-07-10 DEF 14A2026-05-28 8-K2026-05-18 8-K2026-05-14 10-Q2026-05-14 8-K2026-05-08

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.